Table 1.
Characteristics of Included Participants.
| Patient Characteristics | All Port Patients | Matched Patients | ||
|---|---|---|---|---|
| Port n = 50 |
Port n = 40 |
External CVC n = 40 |
||
| Median (Range) | Median (Range) | Median (Range) | P= | |
|
| ||||
|
|
||||
| Age (y) | 7.3 0.7–24 | 6.5 0.7–24 | 2.6 0.5–22 | 0.38b |
| Study period (d) | 162 5–823 | 134.5 5–823 | 211 30–864 | 0.62b |
| PN period (d) | 35 5–229 | 37 5–229 | 55 25–343 | 0.06b |
| n (%) | n (%) | n (%) | P= | |
|
|
||||
| Sex | 0.83c | |||
| Female | 23 (46) | 18 (45) | 19 (47.5) | |
| Male | 27 (54) | 22 (55) | 21 (52.5) | |
| Race | 0.11c | |||
| White | 32 (64) | 24 (60) | 31 (77.5) | |
| Black | 15 (30) | 13 (32.5) | 7 (17.5) | |
| Other or “mixed” | 3 (6) | 3 (7.5) | 2 (5) | |
| CVC typea | N/A | |||
| Port | 50 (100) | 40 (100) | 0 | |
| External CVC | ||||
| Tunneled | 0 | 0 | 38 (87.5) | |
| Non-tunneled | 0 | 0 | 4 (12.5) | |
| Primary malignancy | 1.0c | |||
| Hematologic | ||||
| ALL | 8 (16) | 4 (10) | 6 (15) | |
| Lymphoma | 4 (8) | 1 (2.5) | 1 (2.5) | |
| Other | 3 (6) | 3 (7.5) | 1 (2.5) | |
| Solid tumor | ||||
| Brain tumor | 13 (26) | 13 (32.5) | 12 (30) | |
| Bone tumor | 6 (12) | 5 (12.5) | 5 (12.5) | |
| Other solid tumor | 16 (32) | 14 (35) | 15 (37.5) | |
| HSCT | 6 (12) | 6 (15) | 6 (15) | |
| Number of PN episodes | 0.36c | |||
| 1 | 42 (84) | 32 (80) | 31 (77.5) | |
| 2 | 6 (12) | 6 (15) | 8 (20) | |
| 3 | 2 (4) | 2 (5) | 0 | |
| 4 | 0 | 0 | 1 (2.5) | |
| PN Regimen | 0.25c | |||
| Continuous | 34 (68) | 27 (67.5) | 22 (55) | |
| Cycled or mixed | 16 (32) | 13 (32.5) | 18 (45) | |
HSCT, hematopoietic stem cell transplantation; TPN period, sum of the number of days on which PN was received, or up to 14 days after receiving PN during the study period; ALL, acute lymphoblastic leukemia.
a
4 participants had both tunneled and non-tunneled external catheters during the study period
b
Wilcoxon signed rank test
c
McNemar’s test